CC 8464

Drug Profile

CC 8464

Alternative Names: ASP 1807; CC 8464

Latest Information Update: 17 Oct 2016

Price : $50

At a glance

  • Originator Chromocell Corporation
  • Class Analgesics
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Neuropathic pain
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neuropathic pain
  • Preclinical Diabetic neuropathies; Osteoarthritis; Sciatica

Most Recent Events

  • 12 Oct 2016 Phase-I clinical trials in Neuropathic pain in USA (PO) before October 2016
  • 12 Oct 2016 CC 8464 receives Fast Track designation for Neuropathic pain [PO] in USA
  • 01 Jul 2016 Chromocell Corporation files an IND application with the US FDA in USA for Neuropathic pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top